AI CRISPR 툴 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the aI cRISPR tools market size is projected to be USD 0.78 billion in 2025, USD 0.96 billion in 2026, and reach USD 2.76 billion by 2031, growing at a CAGR of 23.45% from 2026 to 2031.

This report is Segmented by Offering (Software, Hardware, Services), CRISPR Technology (Cas9, Cas12, Cas13, Base Editing, Prime Editing, Other), Application (Drug Discovery, Therapeutic Development, Genomics, Diagnostics, Other), Deployment (Cloud-Based, Hybrid, On-Premises), End User (Pharma, Academic, Cros, Other), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global AI CRISPR Tools Market Trends and Insights

Growing Adoption of AI for Guide RNA Design and Off-Target Prediction

The AI CRISPR tools market is advancing due to improvements in guide RNA design and off-target prediction models. In 2025, a deep learning model, CCLMoff, achieved an AUROC of 0.985 on CIRCLE-seq off-target datasets across 418 single-guide RNAs using sequence input alone. This high prediction accuracy reduces the need for repeated wet-lab screenings, shifting preclinical safety evaluations to in silico filtering. This transition enhances the scalability of design libraries and drives demand for design software and predictive services in therapeutic and discovery programs. Researchers can now test more candidates earlier, minimizing weaker guides in downstream processes.

Expansion of CRISPR Therapeutic Clinical Pipelines Driving Platform Demand

The expansion of clinical CRISPR programs across diverse diseases is driving platform demand in the AI in CRISPR tools market. Each therapeutic program requires ongoing design support for target selection, guide optimization, safety modeling, and manufacturing readiness. Computational engines now support multiple targets, increasing platform demand faster than wet-lab spending. This shift elevates the value of recurring software and workflow services over single product sales. AI tools are becoming critical in rare diseases and personalized medicine, where rapid redesigns and evidence generation are essential. Vendors with validated workflows are positioned to secure larger, long-term contracts as programs approach clinical milestones.

High Complexity and Large Dataset Requirements for AI Model Training in Genomics

The AI CRISPR tools market faces significant challenges due to insufficient data coverage across various editing tasks. A 2025 review analyzed 50 AI predictor studies from 3,456 papers and identified only 80 public benchmark datasets across 10 CRISPR tasks. This limitation causes many models to perform well under specific training conditions but fail to generalize across diverse cell types, species, and CRISPR modalities. Vendors require extensive proprietary datasets to develop reliable tools, but the high cost of generating such datasets favors established players and hinders new entrants. As a result, the market's growth potential is constrained by the difficulty of accessing critical biological data.

Other drivers and restraints analyzed in the detailed report include:

1. Emergence of Foundation Model-Based and Generative AI Nuclease Design Platforms
2. Strategic Pharma-Biotech Alliances Accelerating AI CRISPR Workflow Adoption
3. Regulatory Ambiguity Around AI-Assisted Gene Editing Workflows and Data Governance

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, software dominated the AI CRISPR tools market, capturing 56.20% of the market share. This reflects the critical role of design, analytics, and data management platforms in research and pharmaceutical workflows. Software serves as the control layer for guide design, editing analysis, workflow automation, and data traceability, driving early adoption and higher switching costs. The market is increasingly shaped by platforms that integrate models, experimental data, and compliance requirements.

Benchling's launch of Benchling AI in October 2025 highlighted the evolution of offerings, with features like deep research agents and automated data entry integrated into workflows. The platform served over 1,300 biotech companies and 7,500 academic institutions globally, including major players like Merck and Moderna. Services are projected to grow faster at a 25.05% CAGR through 2031, driven by demand for bundled design, analysis, and execution models. The industry is shifting toward a hybrid model where software anchors workflows, and services expand access for customers lacking internal capabilities.

In 2025, CRISPR-Cas9 held a 37.78% share of the AI CRISPR tools market, maintaining its position as the leading technology. Its dominance is supported by established delivery protocols, safety profiles, and extensive guide design work, which instill user confidence. Many AI models remain optimized around Cas9 datasets, benefiting from the industry's existing knowledge base.

CRISPR-Cas12 is forecast to grow at a 25.76% CAGR through 2031, making it the fastest-growing segment. Its single-stranded DNA collateral cleavage activity supports diagnostics and expands use cases beyond traditional editing workflows. Cas12 is gaining traction due to its precision, diverse targeting behavior, and adaptable platform economics, reflecting a market shift toward broader functional diversity.

Geography Analysis

In 2025, North America held a 42.30% share of the AI CRISPR tools market, maintaining its position as the largest regional contributor. The region benefits from a strong ecosystem of platform developers, financing networks, and advanced cloud infrastructure. The U.S. plays a key role in establishing evidence standards for clinical-stage gene editing programs, further strengthening North America's leadership in commercial adoption of AI CRISPR tools. Asia-Pacific is forecast to grow at a 27.25% CAGR through 2031, making it the fastest-growing region in the AI CRISPR tools market. This growth is driven by increased bioscience investments, expanding development capacity, and rising demand for outsourced research and manufacturing. The region's ability to scale quickly, without legacy system constraints, positions it as a key player in offering service-led solutions.

Europe ranked as the second-largest regional market, supported by research activities in Germany, the United Kingdom, France, Italy, and Spain. Academic and translational research centers in the region contribute significantly to editing design, repair prediction, and target validation. Strong cross-border collaborations further enhance Europe's role as a hub for computational biology and clinical research. South America remained smaller and more nascent, with activity concentrated in Brazil and Argentina. The region is supported by expanding CRO networks and collaborations between government and academia in gene editing applications. These developments highlight the diverse dynamics of the AI CRISPR tools market, with North America leading in commercial depth, Asia-Pacific excelling in growth, and Europe serving as a critical research base.

1. Agilent Technologies
2. ArsenalBio
3. Benchling
4. Broken String Biosciences
5. EvolutionaryScale
6. Inscripta
7. Integrated DNA Technologies / IDT (Danaher)
8. Mammoth Biosciences
9. Merck KGaA (MilliporeSigma)
10. Metagenomi
11. picrisp.ai
12. Profluent Bio
13. Synthego Corporation
14. TeselaGen Biotechnology
15. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Adoption of AI for Guide RNA Design and Off-Target Prediction
  • 4.2.2 Expansion of CRISPR Therapeutic Clinical Pipelines Driving Platform Demand
  • 4.2.3 Rising Investment in AI-Driven Functional Genomics and Target Validation
  • 4.2.4 Falling Compute Costs Democratizing AI-Enabled CRISPR Tool Access
  • 4.2.5 Emergence of Foundation Model-Based and Generative AI Nuclease Design Platforms
  • 4.2.6 Strategic Pharma-Biotech Alliances Accelerating AI CRISPR Workflow Adoption
• 4.3 Market Restraints
  • 4.3.1 High Complexity and Large Dataset Requirements for AI Model Training in Genomics
  • 4.3.2 Regulatory Ambiguity Around AI-Assisted Gene Editing Workflows and Data Governance
  • 4.3.3 Ethical and IP Landscape Complexity Limiting Commercialization Speed
  • 4.3.4 Off Target Effect and Safety Concern
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 Software
  • 5.1.2 Hardware
  • 5.1.3 Services
• 5.2 By CRISPR Technology
  • 5.2.1 CRISPR-Cas9
  • 5.2.2 CRISPR-Cas12 (Cpf1 / Cas12a)
  • 5.2.3 CRISPR-Cas13
  • 5.2.4 Base Editing Systems (CBE and ABE)
  • 5.2.5 Prime Editing Systems
  • 5.2.6 Other CRISPR Systems (CRISPRi/CRISPRa, Epigenome Editing, Novel AI-Designed Variants)
• 5.3 By Application
  • 5.3.1 Drug Discovery and Development
  • 5.3.2 Therapeutic Development
  • 5.3.3 Functional Genomics and Target Identification
  • 5.3.4 CRISPR-Based Diagnostics (Rapid Detection Tools)
  • 5.3.5 Other
• 5.4 By Deployment Model
  • 5.4.1 Cloud-based
  • 5.4.2 Hybrid
  • 5.4.3 On-Premises
• 5.5 By End User
  • 5.5.1 Pharmaceutical and Biotechnology Companies
  • 5.5.2 Academic and Government Research Institutes
  • 5.5.3 Contract Research Organizations (CROs) and CDMOs
  • 5.5.4 Other End Users
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Agilent Technologies
  • 6.3.2 ArsenalBio
  • 6.3.3 Benchling
  • 6.3.4 Broken String Biosciences
  • 6.3.5 EvolutionaryScale
  • 6.3.6 Inscripta
  • 6.3.7 Integrated DNA Technologies / IDT (Danaher)
  • 6.3.8 Mammoth Biosciences
  • 6.3.9 Merck KGaA (MilliporeSigma)
  • 6.3.10 Metagenomi
  • 6.3.11 picrisp.ai
  • 6.3.12 Profluent Bio
  • 6.3.13 Synthego Corporation
  • 6.3.14 TeselaGen Biotechnology
  • 6.3.15 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space and unmet-need assessment